从EMA的经验中吸取教训:过去十年来,营销许可申请中常见的CMC缺陷
Dolores Hernán Pérez de la Ossa1, Friederike Haas1, Robert N Bream1
1European Medicines Agency, Pharmaceutical Quality Office, Human Division, Amsterdam, the Netherlands.
Drug discovery today
|August 3, 2025
概括
本研究分析了新药的欧盟营销许可申请中的质量异议. 识别常见缺陷有助于开发人员达到标准,加速患者获得重要治疗方法.
科学领域:
- 制药科学 制药科学
- 监管事务 监管事务
- 药物开发 药物开发
背景情况:
- 营销许可申请 (MAA) 经过严格的质量审查.
- 欧盟 (EU) 集中程序是新药批准的关键途径.
- 了解审查异议对于有效的药物开发至关重要.
研究的目的:
- 在欧盟的MAA审查期间分析质量方面的主要反对意见 (MO).
- 通过集中程序提交的药物档案中发现常见的缺陷.
- 为开发人员提供见解,以提高档案质量和加快药物获取.
主要方法:
- 对2013年,2018年和2023年的MAA数据的分析.
- 专注于在集中审查过程中提出的质量相关异议.
- 缺陷与产品类型,公共卫生事件,法律变化和指导的相关性.
主要成果:
- 经过十年的欧盟MAA审查发现的常见质量缺陷.
- 缺陷通常与特定的药物类型和不断变化的监管格局有关.
- 异议的趋势凸显了需要开发人员关注的领域.
结论:
- 解决发现的质量缺陷可以简化MAA审查.
- 改进的文件编制提高了对欧盟和全球标准的遵守.
- 减少审查延迟最终可以改善患者获得新药的机会.
更多相关视频
14:14Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
16.0K
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
729
相关概念视频
Drug Regulation
1.8K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.8K
Pharmacovigilance
993
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
993
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Clinical Trials
8.4K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.4K
